The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...

Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...

The combination demonstrated a disease-specific survival rate of 98.7% at 12 months and 96.0% at 36 months. This episode offers practical insights for clinicians navigating complex prostate cancer ...

The group agreed that the future of NMIBC treatment depends on biomarkers that can direct patients toward the therapy most likely to work. The group agreed that treatment selection for ...

Lin Lin, MD, highlights a phase 2 trial of neoadjuvant SAbR followed by surgery in patients with newly diagnosed renal cell carcinoma and caval tumor thrombus. DFS rate was 85.3% at 6 months (95% CI, ...

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...

Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation. Laganosky: The BioProtect rectal spacing device is a ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

Decision-making between ureteroscopy and shock wave lithotripsy involves evaluating clinical evidence, patient preferences, and procedural success rates. Shock wave lithotripsy is noninvasive but may ...

CREST, POTOMAC, KEYNOTE, and ALBAN trials investigate PD-1/PD-L1 inhibitors for BCG-naive bladder cancer patients, focusing on efficacy and safety. Routes of administration vary, with some trials ...

The CLEAR trial demonstrated lenvatinib plus pembrolizumab's superior efficacy over sunitinib in advanced renal cell carcinoma, with robust response rates and significant tumor shrinkage. Sustained ...

Studies show moderate alcohol intake has surprising links to prostate disease. Dr. Parsons is professor of urology, division of urologic oncology, department of urology, Moores UCSD Comprehensive ...